In OCC 2026 Quest for Truth roundtable, leading cardiovascular experts gather to discuss “Heart Failure · Rebirth: Making the Broken Heart Beat Again”. The session is hosted by Prof. Gang Wu, Shanghai General Hospital, and co-moderated by Prof. Xuanxuan Li, Shi Jia Zhuang Great Wall Hospital. Quest for Truth is honored to welcome two distinguished interview guests: Dr. Nazha Hamdani, Ruhr-Universität Bochum; and Prof. Chun Liang, Shanghai Changzheng Hospital.
In this segment, the discussion focuses on how to treat HFpEF and whether the field is moving from slowing deterioration toward protecting myocardial recovery. Prof. Gang Wu asks whether regenerative strategies and RNA-based therapies are close to routine clinical practice, and how early detection and prevention can be advanced through real-world studies.
Dr. Nazha Hamdani emphasizes that HFpEF is not simply diastolic dysfunction, but a complex syndrome involving multiple organs and mechanisms, including atrial fibrillation, right ventricular dysfunction, endothelial dysfunction, inotropic incompetence, and comorbidities such as obesity, diabetes, hypertension, and COPD. She explains that the field is not yet ready for broad regenerative or RNA-based clinical application, because many HFpEF phenotypes and subgroups remain poorly understood. Precise targets and precision medicine are needed for each subgroup.
Prof. Chun Liang notes that more evidence, research, trials, and clinical tools are still needed to improve HFpEF prevention and management. Dr. Hamdani adds that prevention should begin even before patients enter the heart failure stage, by understanding why some people with obesity, diabetes, or hypertension develop HFpEF while others do not. Both experts agree that preventing disease progression is essential, and that earlier intervention may be more powerful than treatment after heart failure has developed.